May is Brain Tumor Awareness Month, a month dedicated to giving a voice to the brain tumor community and raising awareness for a cure. As the largest patient advocacy funder of pediatric brain tumor research and leading champion for families and survivors battling this disease, the Pediatric Brain Tumor Foundation is marking this year’s Brain Tumor Awareness Month by shining a light on the impact that brain cancer has on tens of thousands of children, teens, and survivors across the country.

Unlike other forms of cancer, which have relatively higher survival rates thanks to the medical advancements of the last century, current treatment approaches are not effective on most types of pediatric brain tumors. Brain tumors represent the no. 1 cause of cancer deaths among children, and survivors are left with lifelong side effects because of treatments’ impact on their brain development. Additionally, because the patient population is small, large-scale investments to improve pediatric brain tumor patients’ survival rates and quality of life often take the backseat to other cancer types and diseases.

PBTF’s Brain Tumor Awareness Month campaign “Pediatric brain tumors have a name” shows that children with brain tumors are more than a statistic. They each have a name and story to tell beyond their diagnosis, and we call on the public to help us write the next chapter for every child battling brain cancer.

“A pediatric cancer diagnosis can have a huge impact on a child’s life, but it does not mean they’ve lost their potential or that it’s the only thing that defines them,” shared professional musician and childhood brain tumor survivor Zack Pomerleau in a recent interview with PBTF. “As a child, I was seen as the sick kid who had talent, instead of just a talented kid. My illness had nothing to do with my talent. While my diagnosis is a part of my story that’s given me my perspective today, my talent and love for music are what I want to be known for.”

PBTF is committed to helping all pediatric brain tumor patients, families, and survivors like Zack realize their full potential by:

  • Funding pioneering scientific and public health research: PBTF’s leadership has transformed the pediatric brain tumor landscape, resulting in an improved understanding of the more than 100 types of brain tumors, new therapies and technologies, and multi-million-dollar grants that multiply our impact and lead to more clinical trials. Find out how PBTF’s recent funding of the University of Michigan’s Koschmann Lab helped discover a way to provide doctors faster, more accurate test results for children battling the most aggressive, highest risk brain tumors.
  • Providing families with expert information from the moment symptoms start: No parent is prepared to hear their child has a brain tumor. PBTF is the preferred first point of contact for newly diagnosed families offering essential information informed by leading experts in the field and patient families’ experiences. On May 19, PBTF will host a Brain Tumor Awareness Month webinar for patient families and health care professionals exploring biomarkers’ potential to help families navigate a pediatric brain tumor diagnosis and treatment.
  • Addressing disparities of care within the pediatric brain tumor population: Tragically, racial, social, and economic disparities result in many children with brain tumors not having access to the healthcare they need. The financial costs of treatment frequently worsen existing inequities. PBTF works closely with caregivers and healthcare partners to address the impact that financial insecurity, language, geography, race, and ethnicity have on children’s survival and families’ quality of life through programs like our emergency financial assistance Butterfly Fund. In response to rising gas prices, PBTF is also launching a new program in partnership with five children’s hospitals to offset travel expenses for families driving their children back and forth to medical treatments and appointments.
  • Connecting survivors to effective follow-up care: Pediatric brain tumor survivors face a variety of physical, cognitive, and social challenges that increase and worsen over time. When a survivor reaches adulthood, resources that patients and families depend on frequently disappear, and many are lost to follow-up care entirely. PBTF equips survivors and family members with tools to navigate the effects of pediatric brain tumor treatment, including relationships with loved ones, challenges in school or work, and long-term care.

Curing pediatric brain tumors is a mission PBTF can’t tackle alone. We’re grateful for organizations like Bayer who are supporting our efforts this May to reach more patient families and spread awareness about pediatric brain tumors.

“This Brain Tumor Awareness Month, Bayer is proud to support the Pediatric Brain Tumor Foundation – who have spent decades making continuous strides in addressing the needs of this oftentimes underserved patient population,” said Nelson Ambrogio, Senior Vice President and General Manager, U.S. Oncology at Bayer. “In line with Bayer’s commitment to advance treatment options for pediatric and rare cancers, we recognize the importance of providing education and support for patients and their families facing this devastating disease.”

About the Pediatric Brain Tumor Foundation

Every day, 13 children and teens are diagnosed with a brain tumor, the deadliest childhood cancer. Every day after, they’re in a fight for their life. It’s a fight the Pediatric Brain Tumor Foundation is here to help families win. A leader in the brain tumor and childhood cancer communities, PBTF’s mission of Care. Cure. Thrive. reflects our commitment to curing all pediatric brain tumors and transforming how children and their families are cared for. Since 1991, PBTF has provided strategic leadership and funding to accelerate the number of targeted therapies for children battling brain tumors today, while equipping families with the patient-family education, financial relief, and emotional support they need to navigate their child’s journey. A world without childhood brain tumors is possible when we work together to put kids first. Learn more at www.curethekids.org.

 

Related Updates

Pediatric Brain Tumor Foundation Celebrates FDA Approval of Day One Biopharmaceuticals’ OJEMDA

Drug Development News

Pediatric Brain Tumor Foundation Celebrates FDA Approval of Day One Biopharmaceuticals’ OJEMDA

The FDA has approved Day One Biopharmaceuticals’ OJEMDA (tovorafenib) for treating pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children. The availability of this first-of-its-kind treatment represents an important, long-awaited moment for many pLGG patients. It also marks a significant milestone in the Pediatric Brain Tumor Foundation’s efforts to accelerate new treatment options for all children with brain tumors.

Pediatric Brain Tumor Foundation Awards More Than $1 Million in New Research Funding to Dana-Farber Cancer Institute

Research News

Pediatric Brain Tumor Foundation Awards More Than $1 Million in New Research Funding to Dana-Farber Cancer Institute

The Pediatric Brain Tumor Foundation (PBTF) proudly announces an infusion of $1 million to help researchers, led by Dana-Farber Cancer Institute’s Drs. Pratiti (Mimi) Bandopadhayay and Rameen Beroukhim, launch a study into a novel therapeutic target and expand their research into overcoming treatment resistance and rebound growth.

Name(Required)
This field is for validation purposes and should be left unchanged.